ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Anette Mertens contributed 17 entries already.
The Young European Biotech Network (YEBN) is preparing for a busy semester, with a variety of events and initiatives planned through the end of 2024. From launching a new community platform to hosting key events, YEBN aims to support innovation, facilitate collaboration, and address the evolving needs of the biotech community.
Biotech firm Nuclera raises $75M to expand its cutting-edge protein discovery system, speeding up breakthroughs in labs worldwide.
As a Contract Development and Manufacturing Organization (CDMO), mAbxience is committed to advancing biologics production and to ensuring that patients receive life-saving treatments faster and with uncompromising quality.
DFE Pharma, a world leader in excipients, has expanded into the biopharmaceutical market with its BioHale® portfolio, specifically designed for biologics.
Against the backdrop of Vienna’s historic charm, BIOTECH AUSTRIA, the association for the Austrian biotech industry,
recently invited leading industry representatives to the Vienna Stock Exchange to mark the third anniversary of the association.
Automation: SLAS empowers the global life sciences community to transform research by bringing interdisciplinary researchers and technology providers together to learn, solve challenges and advance life sciences innovation.
Expanding networks: Comprised of passionate individuals committed to driving positive change, YEBN board brings a wealth of diverse experiences and expertise to guide the association towards new heights of success.